Versant Venture Capital VI, L.P. 13D and 13G filings for Monte Rosa Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-10-30 5:10 pm Sale |
2024-10-28 | 13D | Monte Rosa Therapeutics, Inc. GLUE |
Versant Venture Capital VI, L.P. | 4,079,469 6.600% |
-1,019,867 (-20.00%) |
Filing |
| 2024-09-24 5:00 pm Sale |
2024-09-20 | 13D | Monte Rosa Therapeutics, Inc. GLUE |
Versant Venture Capital VI, L.P. | 5,099,336 8.300% |
-1,699,779 (-25.00%) |
Filing |
| 2024-08-12 5:07 pm Unchanged |
2024-08-08 | 13D | Monte Rosa Therapeutics, Inc. GLUE |
Versant Venture Capital VI, L.P. | 6,799,115 11.100% |
0 (Unchanged) |
Filing |
| 2023-11-09 5:26 pm Unchanged |
2023-08-10 | 13D | Monte Rosa Therapeutics, Inc. GLUE |
Versant Venture Capital VI, L.P. | 6,799,115 13.700% |
0 (Unchanged) |
Filing |
| 2021-07-08 4:31 pm Purchase |
2021-06-28 | 13D | Monte Rosa Therapeutics, Inc. GLUE |
Versant Venture Capital VI, L.P. | 6,799,115 15.300% |
6,799,115 (New Position) |
Filing |